PlainPharmaWatch

CMS Open Payments · Program Year 2024

Urogen Pharma, Inc.

Urogen Pharma, Inc. reported $2,314,135.46 across General Payments, Research, and Ownership to 7,857 physicians and teaching hospitals across 8,060 transactions.

$2.3M
All-tracks total
8,060
Transactions
7,857
Recipients
+$120.7K
General Payments vs PY2023

Urogen Pharma, Inc. reported $2,314,135.46 across all CMS Open Payments tracks (General + Research + Ownership) to 7,857 physicians and teaching hospitals in Program Year 2024 - ranking #419 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,592,849.71, averaging $294.53 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer urogen-pharma-inc Urogen Pharma, Inc.

$2.3M · #419/1,925 · 0.0% industry · PY2024

  • TOT $2.3M
  • RANK #419
  • SHARE 0.0%
  • TXN 8,060
  • RCP 7,857
  • CAT 8
  • GEN $1.6M
  • ΔGEN +$120.7K
  • TOP1 19.3%
  • PY 2024

Nearest volume peer: Albireo Pharma, Inc. ($2.3M)

Checkpoint Surgical, Inc$2.3MUrogen Pharma, Inc. (this)$2.3MAlbireo Pharma, Inc.$2.3MEthicon Endo-Surgery Inc.$2.3MAimmune Therapeutics, Inc.$2.3M
All-tracks payment totals near Urogen Pharma, Inc. (CMS Open Payments PY2024)

Urogen Pharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Urogen Pharma, Inc.'s CMS-reported General Payments increased by $120.7K (+8.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: UROGEN PHARMA, INC.PY2023: UROGEN PHARMA, INC.PY2024: UROGEN PHARMA, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.5MPY2024$1.6M
PY2023
$1,472,180.03
PY2024
$1,592,849.71

What the Data Shows for Urogen Pharma, Inc.

In Program Year 2024, Urogen Pharma, Inc. reported $2,314,135.46 in payments to 7,857 physicians and teaching hospitals across 8,060 individual transactions, an average of $287.11 per transaction and $294.53 per recipient. That total places Urogen Pharma, Inc. at rank #419 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

20 transactions worth $768.9K make "Compensation for Services Other Than Consulting" the top general-payment category in the 8-category breakdown below, 48.3% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Urogen Pharma, Inc. made 8 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $768.9K, 48.3% of General Payments.

Urogen Pharma, Inc. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (48.3%), Honoraria (24.1%), and Food and Beverage (15.9%). The remaining 5 categories make up 11.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

Category breadth matters here: Urogen Pharma, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.

How Urogen Pharma, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Compensation for Services…$768.9K2. Honoraria$384.6K3. Food and Beverage$253.5K4. Consulting Fee$99.9K5. Travel and Lodging$58.9K6. Space Rental or Facility …$18.9K7. Gift$7.0K8. Education$1.1K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $768.9K 20
Honoraria $384.6K 108
Food and Beverage $253.5K 7,473
Consulting Fee $99.9K 46
Travel and Lodging $58.9K 134
Space Rental or Facility Fees $18.9K 6
Gift $7.0K 28
Education $1.1K 42

Recipient Concentration in General Payments

The five largest recipient relationships account for $902,238.51 (56.6%) of $1,592,849.71 in this company's General Payments records across 4,018 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Urogen Pharma, Inc.

The five named recipients with the highest reported General Payments from this company

Arie Belldegrun$308.2KLeana Sheryle Wen$167.3KStuart Holden$157.9KFred E Cohen$153.4KKatie S Murray$115.5K
  1. 1

    Arie Belldegrun

    $308,197.45 across 12 reported transactions

  2. 2

    Leana Sheryle Wen

    $167,292.30 across 17 reported transactions

  3. 3

    Stuart Holden

    $157,852.94 across 15 reported transactions

  4. 4

    Fred E Cohen

    $153,371.36 across 9 reported transactions

  5. 5

    Katie S Murray

    $115,524.46 across 96 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Urogen Pharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Urogen Pharma, Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Urogen Pharma, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Urogen Pharma, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.